A common vaccine might also protect the aging brain
Researchers led by Kaley Hayes at the University of Massachusetts tracked older adults freshly discharged from skilled nursing facilities, a population already at high risk for both shingles and new-onset dementia.
Comparing those who received the newer recombinant shingles vaccine, sold as Shingrix, against those who didn't, the team found a lower rate of dementia diagnosis over a four-year period, enough that they estimate the shot could prevent roughly one in every 17 cases [196]. It builds on an older, discontinued shingles vaccine that showed the same signal, and on the theory that shingles itself inflames the brain and raises stroke risk, so muting the virus might mute that damage too.